Financiere des Professionnels Fonds d investissement inc. Has $10.88 Million Stake in Johnson & Johnson (NYSE:JNJ)

Financiere des Professionnels Fonds d investissement inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,581 shares of the company's stock after selling 1,994 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.'s holdings in Johnson & Johnson were worth $10,876,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.5%

JNJ stock traded down $0.82 during trading on Friday, hitting $156.87. The company had a trading volume of 7,866,488 shares, compared to its average volume of 8,066,975. The business has a 50-day moving average of $153.73 and a 200-day moving average of $154.35. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market cap of $377.44 billion, a PE ratio of 17.45, a PEG ratio of 2.15 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson's payout ratio is 57.84%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JNJ. Raymond James Financial dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Bank of America dropped their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $171.00.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.